1Rubin BK. Immunomodulatory properties of macrolides: overview and historical Perspective[J]. Am J Med, 2004,117 :Suppl. 9A, 2-4.
2Fujii T, Kadota J, Kawakami K, et al. Long term effect of eryth- romycin therapy in patients with chronic Pseudomonas aeruginosa infection[ J]. Thorax 1995 ; 50 : 1246 - 1252.
3Li H, Zhou Y, Fan F, et al. Effect of azithromycin on patients with diffuse panbronchiolitis : retrospective study of 521 cases[ J]. Intern Med, 2011; 50:1663-1669.
4Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fi- brosis: strategies that increase life expectancy and improve quality of life[J]. Am J Respir Crit Care Med, 2011,183 : 1463 - 1471.
5Waters V, Yau Y, Prasad S, et al. Stenotrophomonas maltophilia in cystic fibrosis:serologic response and effect on lung disease [ J ]. Am J Respir Crit Care Med, 2011,183: 635 -640.
6Saiman L, Mayer-Hamblett N, Anstead M, et al. Open-label, fol- low-on study of azithromycin in paediatric patients with CF unin- fected with Pseudomonas aeruginosa[ J]. Pediatr Pulmonol, 2012, 47:641 -648.
7Lisa S, Nicole MH, Preston C, et al. Heterogeneity of treatment re- sponse to azithmmycin in patients with cystic fibrosis [ J ]. Am J Respir Crit Care Med, 2005,172 : 1008 - 1012.
8Southern KW, Barker PM, Solis-Moya A, et al. Macrolide antibi- otics for cystic fibrosis[ J]. Cochrane Database Syst Rev, 2011, 11 : CD002203.
9Wong C, Jayaram L, Karalus N, et al. Azithromycin for preven- tion of Exacerbations in non-cystic fibrosis bronchiectasis ( EM- BRACE): a randomized, double-blind, placebo-controlled trial [J]. Lancet, 2012,380:660-667.
10Huang YJ, Nelson CE, Brodie EL, et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally con- trolled asthma[J]. J Allergy Clin Immunol, 2011,127:372 - 381.
